What is Mendelian Randomization and How Can it be Used as a Tool for Medicine and Public Health? Opportunities and Challenges
November 27, 2018, 3:00-4:00 pm ET
Free Online Webinar; Free Registration is required: REGISTER HERE
Professor George Davey Smith
MA Oxon. MB B.Chir (Cantab), MSc (London), MD (Cantab), DSc (Oxon)and Professor of Clinical Epidemiology
Bristol Medical School: Population Health Sciences
Bristol, United Kingdom
Dr. Davey Smith will give an overview of the field of Mendelian Randomization, and the opportunities it provides for assessing causal inference in medicine and public health, some of its methodologic limitations, as well as related approaches than can contribute to precision medicine and population health. He will use examples from cancer, cardiovascular diseases and other fields to illustrate this approach (40 minutes)
Discussion: This includes Q&As with speaker about his presentation. We will also focus on the future science agenda for Mendelian Randomization. (20 minutes)
Mendelian randomization is a method of using measured variation in genes of known function to examine the causal effect of a modifiable exposure on disease in observational studies. The term was first proposed by Gray and Wheatley in 1991 for a method that could obtain unbiased estimates of the effects of cancer treatment within a family based design. The term has since been applied to studies that use genetic variants reliably related to a modifiable risk factor to obtain evidence regarding the causal influence of the risk factor. This is achieved through the properties that genetic variants have that render them not susceptible to reverse causation and confounding, which otherwise bedevil epidemiological studies.
- A two minute primer on mendelian randomisation
- Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?
G Davey Smith, S Ebrahim, Int J Epidemiol 2003 Feb;32(1):1-22.
- Mendelian randomization
CA Emdin et al, JAMA, Nov 21, 2017
- Mendelian Randomization: How the Natural Assortment of Genes Can Mimic Randomized Clinical Trials
JAMA Podcast, Nov 21, 2017
- Mendelian Randomization Evidence for Cardiovascular Precision Medicine
C O’Donnell, JAMA Cardiology, June 20, 2018
- Using genetic data to strengthen causal inference in observational research
JB Pingault et al, Nat Rev Genetics, June 5, 2018
- Genetic epidemiology and Mendelian randomization for informing disease therapeutics: Conceptual and methodological challenges
L Paternoster et al. PLoS Genetics 2017 Oct 13(10) e1006944
- Mendelian randomization: where are we now and where are we going?
S Burgess et al. Int J Epidemiology 2015;44(2):379-388.
- Mendelian randomization in cardiometabolic disease: challenges in evaluating causality
Holmes MV, Ala-Korpela M, Davey Smith G. Nature Reviews Cardiology 2017;14:577-590
- Precision Medicine and Population Health Interest Group, Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health
- Center for Translation Research and Implementation Science, National Heart, Lung and Blood Institute, National Institutes of Health
- Office of Public Health Genomics, Centers for Disease Control and Prevention